Literature DB >> 26104767

Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer.

Jing Jia1, Xiongwei Zheng1, Ying Chen2, Lin Wang1, Lu Lin1, Xingming Ye1, Yan Chen1, Dedong Chen1, Markus Dettke3.   

Abstract

This study aims to assess the association of the preoperative neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) with tumor stage in colorectal cancer (CRC) patients. A retrospective study was performed in 336 CRC patients. Preoperative whole blood counts, serum levels of carcinoembryonic antigen (CEA), and clinicopathologic data were collected. The correlations between laboratory parameters and the tumor, node, and metastasis (TNM) stages were analyzed. The clinicopathologic TNM stages among CRC patients were 12.8 % at stage I, 32.4 % at stage II, 44.6 % at stage III, and 10.1 % at stage IV. NLR, PLR, and CEA levels were higher in CRC patients compared to healthy controls (all P < 0.0001). Both NLR and PLR showed an early elevation as compared to CEA, with a higher area under curve (AUC) value (0.71 vs. 0.62) in predicting the presence of the tumor with stage I/II. Accordingly, significant elevations of NLR (P = 0.0018) and PLR (P < 0.0001) were firstly detected in stage I and stage II, respectively. In addition, NLR exhibited a second phase elevation in stage IV, with a significant higher level in M1 subgroup compared to M0 subgroup (P = 0.022). While PLR showed a T stage-dependent increase (P = 0.0003) and was identified as an independent factor for the T grade development (P < 0.0001). Our data indicated that both neutrophil- and platelet-mediated inflammatory reactions are predominantly involved in the different stages of CRC development. Determination of pretreatment levels of NLR and PLR might provide useful information for the early diagnosis or the therapeutic choices in CRC patients.

Entities:  

Keywords:  Colorectal cancer; Neutrophil to lymphocyte ratio; Platelet to lymphocyte ratio; TNM stage

Mesh:

Year:  2015        PMID: 26104767     DOI: 10.1007/s13277-015-3667-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

Review 1.  Inflammation and colorectal cancer: colitis-associated neoplasia.

Authors:  Sergei I Grivennikov
Journal:  Semin Immunopathol       Date:  2012-11-16       Impact factor: 9.623

2.  [Preoperative platelet-lymphocyte ratio is an independent prognostic factor for resectable colorectal cancer].

Authors:  Hailiang Liu; Xiaohui DU; Peiming Sun; Chunhong Xiao; Yingxin Xu; Rong Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2013-01

Review 3.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

Review 4.  Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Authors:  Arnoud J Templeton; Olga Ace; Mairéad G McNamara; Mustafa Al-Mubarak; Francisco E Vera-Badillo; Thomas Hermanns; Boštjan Seruga; Alberto Ocaña; Ian F Tannock; Eitan Amir
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-03       Impact factor: 4.254

5.  Neutrophil-lymphocyte and platelet-lymphocyte ratios as prognostic factors after stereotactic radiation therapy for early-stage non-small-cell lung cancer.

Authors:  Nathan A Cannon; Jeffrey Meyer; Puneeth Iyengar; Chul Ahn; Kenneth D Westover; Hak Choy; Robert Timmerman
Journal:  J Thorac Oncol       Date:  2015-02       Impact factor: 15.609

Review 6.  Colorectal cancer.

Authors:  Hermann Brenner; Matthias Kloor; Christian Peter Pox
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

7.  Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma.

Authors:  Serta Kilincalp; Şahin Çoban; Hakan Akinci; Mevlüt Hamamcı; Fatih Karaahmet; Yusuf Coşkun; Yusuf Üstün; Zahide Şimşek; Elife Erarslan; İlhami Yüksel
Journal:  Eur J Cancer Prev       Date:  2015-07       Impact factor: 2.497

8.  Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer.

Authors:  W Chua; K A Charles; V E Baracos; S J Clarke
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

Review 9.  The diagnostics of colorectal cancer.

Authors:  Magdalena Swiderska; Barbara Choromańska; Ewelina Dąbrowska; Emilia Konarzewska-Duchnowska; Katarzyna Choromańska; Grzegorz Szczurko; Piotr Myśliwiec; Jacek Dadan; Jerzy Robert Ladny; Krzysztof Zwierz
Journal:  Contemp Oncol (Pozn)       Date:  2013-12-20

10.  Prognostic value of PLR in various cancers: a meta-analysis.

Authors:  Xin Zhou; Yiping Du; Zebo Huang; Jun Xu; Tianzhu Qiu; Jian Wang; Tongshan Wang; Wei Zhu; Ping Liu
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more
  24 in total

1.  The Lymphocyte-Monocyte Ratio and the Platelet-Lymphocyte Ratio at Diagnosis as Independent Prognostic Factors in Primary Gastrointestinal Diffuse Large B Cell Lymphoma.

Authors:  Pan Zhao; Li Zang; Xiaoying Zhang; Yafang Chen; Hongliang Yang; Haifeng Zhao; Yong Yu; Yafei Wang; Yizhuo Zhang; Xiaofang Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2016-08-29       Impact factor: 0.900

2.  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios may aid in identifying patients with non-small cell lung cancer and predicting Tumor-Node-Metastasis stages.

Authors:  Fei Xu; Pengliang Xu; Wenqiang Cui; Weiyi Gong; Ying Wei; Baojun Liu; Jingcheng Dong
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

3.  The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsunari Fukuoka; Shinji Matsutani; Kenjiro Kimura; Ryosuke Amano; Kosei Hirakawa; Masaichi Ohira
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

4.  Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC.

Authors:  Hong-Xin Peng; Lin Yang; Bang-Shun He; Yu-Qin Pan; Hou-Qun Ying; Hui-Ling Sun; Kang Lin; Xiu-Xiu Hu; Tao Xu; Shu-Kui Wang
Journal:  J Clin Lab Anal       Date:  2016-09-30       Impact factor: 2.352

5.  The diagnostic value of preoperative inflammatory markers in craniopharyngioma: a multicenter cohort study.

Authors:  Ming Chen; Shi-Hao Zheng; Min Yang; Zhi-Hua Chen; Shi-Ting Li
Journal:  J Neurooncol       Date:  2018-01-31       Impact factor: 4.130

6.  Stage predictivity of neutrophil/lymphocyte and platelet/lymphocyte ratios in pancreatic neuroendocrine tumors.

Authors:  Kürşat Dikmen; Mustafa Kerem
Journal:  Turk J Surg       Date:  2020-03-18

7.  Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer.

Authors:  Chao Liu; Zhou Huang; Qiusheng Wang; Bing Sun; Lijuan Ding; Xiangying Meng; Shikai Wu
Journal:  Onco Targets Ther       Date:  2016-07-27       Impact factor: 4.147

8.  Predictive value of hematological markers of systemic inflammation for managing cervical cancer.

Authors:  Lin Wang; Jing Jia; Lu Lin; Junying Guo; Xingming Ye; Xiongwei Zheng; Ying Chen
Journal:  Oncotarget       Date:  2017-07-04

9.  Prognostic efficacy of inflammation-based markers in patients with curative colorectal cancer resection.

Authors:  Özgür Akgül; Erdinç Çetinkaya; Metin Yalaza; Sabri Özden; Mesut Tez
Journal:  World J Gastrointest Oncol       Date:  2017-07-15

10.  Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.

Authors:  Wangqiang Jia; Long Yuan; Hongyan Ni; Benling Xu; Peng Zhao
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.